<p><strong>Pediatric Use</strong>: Safety and effectiveness of Pegfilgrastim in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: Of the 932 patients with cancer who received Pegfilgrastim in clinical studies, 139 (15%) were age 65 and over, and 18 (2%) were age 75 and over. No overall differences in safety or effectiveness were observed between patients age 65 and older and younger patients.<br />
<br />
<strong>Renal Impairment</strong>: In a study of 30 subjects with varying degrees of renal dysfunction, including end stage renal disease, renal dysfunction had no effect on the pharmacokinetics of Pegfilgrastim. Therefore, Pegfilgrastim dose adjustment in patients with renal dysfunction is not necessary.</p>